Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6545978 | 0.80 | — | — | |
| SCHEMBL3322875 | 0.70 | — | — | |
| SCHEMBL786437 | 0.70 | NOS3 (0.31) | — | |
| SCHEMBL8528797 | 0.69 | — | — | |
| SCHEMBL8528800 | 0.69 | — | — | |
| Hydrochloric Acid SCHEMBL28150542 | 0.68 | NOS3 (0.30) | — | |
| SCHEMBL13034847 | 0.68 | — | — | |
| SCHEMBL4616815 | 0.68 | — | — | |
| Ammonia Solution, Strong SCHEMBL28135320 | 0.68 | NOS3 (0.30) | — | |
| SCHEMBL18595029 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200255413-A1 | ANTIBACTERIAL COMPOUNDS | BLACKSMITH MEDICINES, INC. | 2020-08-13 | — | — | US | disclosed |
| US-20200188536-A1 | CHLOROTOXIN CONJUGATES AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. | 2020-06-18 | — | — | US | disclosed |
| US-20190225628-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-07-25 | — | — | US | disclosed |
| US-9981930-B1 | MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225628-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | MAPT 4167/4885 |
| US-20200255413-A1 | ANTIBACTERIAL COMPOUNDS | SPOUT1, MRPL21, NRDC | MAPT 2641/4885 |
| US-20200188536-A1 | CHLOROTOXIN CONJUGATES AND METHODS OF USE THEREOF | CHLSN, QPCT, CBX6 | MAPT 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.